The Ministry of Justice has disclosed, via an announcement, its plans to ease restrictions on state-licensed medical cannabis. This move is anticipated to foster greater research opportunities and enhance treatment options for patients.
Subscribe to read this article without ads
Gain unlimited access to ad-free content and exclusive articles.
Acting Attorney General Todd Blanche stated in a post,
introducing Schedule I drugs like heroin, ecstasy, and LSD. These are deemed more dangerous and tightly regulated, and advocates are optimistic about the potential rescheduling of cannabis.
Blanche indicated that FDA-approved marijuana and state-approved varieties will be classified as Schedule III drugs. This category is designated for “drugs with a moderate to low potential for physical and psychological dependence.”
The Ministry of Justice mentioned in a press release that a hearing on June 29 will consider “significant changes to marijuana’s classification under federal law.”
“The Department of Justice is fulfilling President Trump’s promise to broaden healthcare options for Americans,” Blanche remarked. “This reclassification will promote research into the safety and efficacy of cannabis, ultimately benefiting patient care and equipping physicians with credible information.”
On Wednesday, a White House representative conveyed to NBC News that the administration is acting “swiftly” to execute President Trump’s executive orders, aimed at relaxing cannabis regulations and enhancing medical research to bridge the gap between existing medical marijuana usage and scientific understanding.
President Trump issued an executive order in December to expedite the reclassification of marijuana. This initiative is not intended to legalize cannabis at the federal level.
Following the executive order, NBC News reported that researchers expressed high hopes that reclassifying cannabis would expand research avenues and improve understanding of its medical implications.
Advocates, including various medical professionals, argue that medical cannabis can aid in alleviating symptoms associated with severe or chronic pain, terminal illnesses, and cancer. Yet, critics warn that cannabis usage during childhood and early adulthood may negatively impact cognitive functions related to attention, memory, and learning capabilities. Concerns also exist regarding the long-term impact of cannabis on male fertility.
Cannabis was classified as a Schedule I drug during the Nixon administration.
NBC News has reached out to the White House for comments regarding the Justice Department’s recent announcement.
Source: www.nbcnews.com
